Compare Gap Inc (GAP) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs GSK plc — how do they compare? Gap Inc trades at $20.7 (market cap $7.74B), while GSK plc trades at $51.15 (market cap $104.15B). The key difference: GSK plc is far larger — about 13.5× Gap Inc's market cap, and GSK plc pays the higher dividend (3.48%). Which is the better fit depends on your goals.
| GAP | GSK | |
|---|---|---|
Market Cap | $7.74B | $104.15B |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $61.18 |
52-Week Low | $18.35 | $38.22 |
Enterprise Value | $10.82B | $124.56B |
Dividend Yield | 3.25% | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap trades at $20.47, down 0.24% on the day, with a bullish technical signal supported by strong momentum indicators. The stock shows attractive valuation metrics, including a P/E of 8.12 and P/S of 0.51, while recent earnings have generally beaten expectations. Operating cash flow remains robust at $1.49 billion for 2025, and the company continues its digital transformation with AI initiatives.
The outlook is positive with a consensus price target of $26.64, implying 30% upside. Risks include competitive pressures and ongoing investigations by Pomerantz Law Firm. Analyst sentiment is mixed but leans bullish, with 39.58% recommending buy. The stock presents a value opportunity if turnaround efforts sustain momentum.
GSK trades at $52.96, up 1.51% today, with strong technical momentum showing bullish moving averages and neutral oscillators. The company delivered three consecutive earnings beats in 2026, with Q2 EPS of $1.36 beating estimates by 7%. Recent FDA approval for Jideytro lung cancer therapy and a $2.52 billion cost-saving initiative support growth prospects. Valuation metrics remain reasonable with P/E of 16.69 and EV/EBITDA of 9.68.
GSK presents a balanced investment case with solid fundamentals and pipeline progress offset by margin pressure risks. The company's 29.73% ROE and consistent dividend payments provide shareholder value, while competitive pressures and patent expirations require careful monitoring. Analyst consensus leans Hold (55%) with 31% Buy ratings, suggesting cautious optimism for the pharmaceutical giant's transformation under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
